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Summary: The plasma level of carnitine, a co-factor involved in many metabolic reactions, is high in alcoholic
liver cirrhosis, due to an increased amount of esterified carnitine. To determine if this alteration is linked to
alcoholic liver disease or to liver cirrhosis per se, total carnitine, free carnitine, total esterified carnitine, short
chain acylcarnitine and long chain acylcarnitine were measured in 41 patients suffering from liver cirrhosis
of different aetiology and severity. In 19 of these patients, acetylcarnitine was also measured. Moreover,
multivariate analysis was performed to assess the association of carnitine plasma levels with nutritional and
liver disease indices.
Of the nutritional indices (creatinine/height ratio, mid upper arm muscle circumference and triceps skinfold)
only triceps skinfold appeared to be weakly correlated with carnitine (with long chain acylcarnitine).
Significantly high levels of acetylcarnitine, short chain acylcarnitine, total esterified carnitine and total carnitine
were found in cirrhotics independently of the aetiology of cirrhosis, even though a trend towards higher levels
of acetylcarnitine was evident in heavy drinkers.
Direct correlations of -glutamyltransferase with acetylcarnitine, acetylcarnitine/free carnitine, short chain
acylcarnitine/free carnitine and total esterified carnitine/free carnitine were found. Carnitine plasma levels did
not differ in the three Pugh-Chiltfs classes; however, a trend towards higher levels of acetylcarnitine was
found in Pugh-ChilcTs class C.
In conclusion, the high levels of acetylcarnitine, short chain acylcarnitine, total esterified carnitine and total
carnitine found in cirrhosis were linked to liver disease. Alcohol abuse seemed only to be an exacerbating
factor.
Introduction , . . . - .In humans the last enzyme in carnitine synthesis, -
L-Carnitine (L-(-)-hydroxy-4-trimethylaminobutyr- butyrobetaine hydroxylase, is present only in liver
ate) is an ubiquitous molecule in animal tissues in- and kidney and, in small amounts, in brain (7). There-
volved primarily in the ß-oxidation of long chain fatty fore, carnitine for the metabolic needs of all other
acids (1). A carrier process involving carnitine is es- tissues is provided by synthesis in the liver and kidney,
sential for long chain fatty acid transport across the and by the alimentary intake. Plasma carnitine con-
inner mitochondrial membrane so that they may reach stitutes the pool supplying all the tissues where car-
the mitochondrial matrix where ß-oxidation occurs nitine synthesis cannot be carried out. In plasma,
(2). carnitine is present as free carnitine (molecule without
However, carnitine is also implicated in liver ketogen- an attached acyl group) and esterified carnitine. Es-
esis (3), in buffering the intracellular acyl-CoA/CoA terified carnitine comprises a group of carnitine acyl-
ratio (4), in the oxidation of branched chain amino esters with carbon-chain of different length. Accord-
acids (5) and in peroxisomal ß-oxidation (6). ing to their acid solubility, acylcarnitines are subdi-
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vided into short-chain acylcarnitine, in which the acyl
moiety contains less than 10 carbon atoms, and long-
chain acylcarnitine, in which the acyl moiety contains
more than 10 carbon atoms. The ratios between the
fractions of carnitine in plasma is considered to ex-
press the corresponding ratios in hepatic tissue (2)
which, in turn, reflects the acylation of coenzyme A
in liver tissue (8).
In liver cirrhosis, both reduced liver synthesis or mal-
nutrition could account for the low carnitine plasma
levels found by Rudman et al. (9). However, more
recently Fuller et al. (10) and Cooper et al. (11) did
not find hypocarnitinaemia in alcoholic liver disease.
They actually found high levels of total carnitine, due
to an increased amount of esterified carnitine in
chronic alcoholic liver disease. However, it is not clear
if this finding is linked to alcohol, or to liver disease
per se. Moreover, some authors (12) have reported a
relationship between the severity of liver disease and
the level of esterified carnitine, whereas others (10,
13) have not found this.
To clarify whether the alterations of carnitine plasma
levels in liver cirrhosis are linked to alcohol con-
sumption, to the severity of liver damage, or to the
nutritional status of patients, a transversal study was
carried out on inpatients suffering from liver cirrhosis
of different aetiology and severity.
In cirrhotics, significantly increased levels of short
chain acylcarnitine and a trend towards increased
acetylcarnitine accounted for higher levels of esterified
and total carnitine which did not depend primarily
on alcohol abuse, or on nutritional status. Liver dis-
ease per se seemed to be implicated in altered carnitine
plasma levels.
Materials and Methods
We studied 41 patients (27 males and 14 females) aged 55 + 11
years (mean + S.D.) suffering from liver cirrhosis, and 16
healthy controls (11 males and 5 females) aged 43 + 13 years.
Twenty three patients had alcoholic cirrhosis, 4 HBsAg positive
cirrhosis, 13 cryptogenic cirrhosis and 1 biliary cirrhosis. Di-
agnosis was by case history and clinical findings, and confirmed
by liver biopsy in 37 cases; 17 had ascites. No one suffered
from gastrointestinal bleeding in the month prior of the study.
Seven cirrhotics were in Pugh-Childs class A, 20 in class B and
14 in class C. All were discharged alive from the hospital.
Diets were variable. Those with ascites received a sodium re-
stricted diet with 58 g of protein, 40 mg (250 μιηοΐ) of carnitine,
2.7 g (18.8 mmol) of lysine and 0.85 g (5.7 mmol) of methionine
daily, the others received a free hospital diet containing about
70 g of protein, 60 mg (370 μπιοί) of carnitine, 3.2 g (21.9 mmol)
of lysine and 1.10 g (7.4 mmol) of methionine daily.
The nutritional status was assessed by:
1) the ratio of 24 hours creatinine excretion to height (creati-
nine/height ratio),
2) the mid upper arm muscle circumference calculated according
to the formula: mid upper arm muscle circumference = arm
circumference — π χ skinfold,
3) the triceps skinfold measured with a caliper.
The nutritional indices and the main liver function indices
(measured with a routine commercial kit from Boehringer,
West-Germany) are summarized in table 1. In all patients renal
function was assessed by measuring creatinine clearance. In two
of them it was severely reduced (8 and 18 ml/min).
Blood samples drawn between 7 a. m. and 8 a. m. after an
overnight fast were collected into heparinized tubes and the
plasma separated by centrifugation. Plasma samples of all cir-
rhotics and controls were assayed for total carnitine, short chain
acylcarnitine, and long chain acylcarnitine according to Di
Donato (14); acetylcarnitine was measured according to Cooper
et al. (15) in 19 cirrhotics and in 3 controls. The reproducibility
(% coefficient of variation) 2—4%.
Statistics
The comparison of carnitine plasma levels and esterification
ratios in cirrhotics and controls was carried out by the Mann-
Whitney's test on the ranked values, because they did not fit
the Gaussian distribution in the goodness of fit test. Only long
chain acylcarnitine and long chain acylcarnitine/free carnitine
were found to be normally distributed, so they were compared
by the Student's t test. Even though carnitine plasma levels are
higher in men (16), we did not subdivide our series in relation
to sex to compare controls and cirrhotics, because the females/
males ratio was comparable in the two groups.
The relationship of carnitine plasma levels and esterification
ratios with the degree of hepatic disease, expressed by the Pugh-
Childs class, was evaluated by the Spearman's test. Spearman's
rank correlation was also used to assess possible associations
between carnitine plasma levels and creatinine clearance.
To ascertain the degree of association of nutritional and liver
disease indices with plasma carnitine, step by step multivariate
analysis was done, using "Microstat" software (Ecosoft, Inc.
1987).
Tab. 1. Summary of the main clinical and biochemical data in cirrhotic patients.
Alanine aminotransferase
Aspartate aminotransferase
γ-Glutamyltransferase
Alkaline phosphatase
Bilirubin
Prothrombin time
71 + 57U/1
83 + 61 U/l
185 + 21 3 U/l
160 + 97 U/l
29 + 50 mg/1
58 + 12%
Albumin
Triceps skinfold
Creatinine/height ratio
Mid upper arm circumference
Creatinine
34 + 7g/l
13.3 + 6.6mm
83 + 34%
24 ± 2 cm
1.0+ l.Omg/dl
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Results
Cirrhotics had higher levels of total and esterified
carnitine with more widespread distributions which
were not Gaussian (fig. 1). Only long chain acylcar-
nitine was substantially unchanged in cirrhotics com-
pared with controls.
The short chain acylcarnitine/free carnitine ratio was
significantly higher in cirrhotics; they also showed a
trend towards a higher acetylcarnitine/free carnitine
ratio (tab. 2).
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Fig. l. Plasma levels of total carnitine and of its fractions in controls (shadowed) and in cirrhotics.
Each point represents one cirrhotic patient. Identical values of different patients are drawn horizontally.
Cirrhotics*
Controls*
U
t
P
53 + 20
44 ± 11
211
<0.02
39 + 14
36 ± 7
301
<0.35
14 + 9
8 ± 6
171
< 0.003
1.1 + 0.3
1.0 ± 0.3
1.44
<0.1
13 + 9
7 ± 6
117
< 0.004
8 ± 5
5± 1
10
<0.05
values in mmol/1
Tab. 2. Mean values of the esteriiication ratios of carnitine in cirrhotics and controls.
Cirrhotics Controls U
Acetylcarnitine/free carnitine
Short-chain acylcarnitine/free carnitine
Long-chain acylcarnitine/free carnitine
Total esterified carnitine/free carnitine
0.21 + 0.16
0.36 + 0.26
0.032 + 0.012
0.39 + 0.26
0.14 + 0.03
0.18 + 0.17
0.027 + 0.007
0.23 + 0.18
18
159
1.33*
186
0.150
0.001
0.098
0.006
* t value
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Carnitine and nutrit ion
No relationship was found between nutritional indices
and carnitine plasma levels or carnitine esterification
ratios, with the exception of a weak direct correlation
between triceps skinfold and long chain acylcarnitine
(fig- 2).
10 15 20 25 30
Triceps skinfold [mm]
Fig. 2. Correlation between triceps skinfold and long-chain
acylcarnitine.
N = 23, r = 0.39, p = 0.052
Carnitine and liver function
As far as the indices of liver disease are concerned,
γ-glutamyltransferase showed the higher correlation
with carnitine metabolism: γ-glutajnyltransferase
plasma activity was found to be directly correlated
with acetylcarnitine (partial r2 = 0.60, P < 0.01), acyl-
carnitine/free carnitine (partial r2 = 0.45, P < 0.01),
short chain acylcarnitine/free carnitine (partial
r2 = 0.38, P < 0.05) and total esterified carnitine/free
carnitine (partial r2 = 0.38, P < 0.05) (fig. 3). Also
albumin showed a weak, inverse correlation with ace-
tylcarnitine (partial r2 = 0.036, P = 0.05). Moreover,
weak direct correlations between alkaline phosphatase
and short chain acylcarnitine (partial r2 = 0.12,
P < 0.05) and between alkaline phosphatase and total
esterified carnitine (partial r2 = 0.12, P < 0.05) were
found.
Carnitine and the severity of cirrhosis
Plasma carnitine levels and carnitine esterification did
not differ significantly in the three Pugh-ChilcFs
classes. However a trend towards higher levels of
acetylcarnitine in class C was evident (tab. 3).
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Fig. 3. Correlations of γ-glutamyltransferase with acetylcarnitine and the ratios of the acetylcarnitine/free carnitine ratios, short
chain acylcarnitine/free carnitine ratios, and total esterified carnitine/free carnitine ratios.
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Tab. 3. Carnitine plasma levels and esterification ratios in the three classes of Pugh-Child.
A B
Total carnitine
Free carnitine
Total esterified carnitine
Acetylcarnitine
Short-chain acylcarnitine
Long-chain acylcarnitine
Total esterified carnitine/free carnitine
Acetylcarnitine/free carnitine
Short-chain acylcarnitine/free carnitine
Long-chain acylcarnitine/free carnitine
(mmol/1)
(mmol/1)
(mmol/1)
(mmol/1)
(mmol/1)
(mmol/1)
53 + 13
38 ± 11
15 + 13
6 ± 2
14 -l· 13
1.1 + 0.5
0.48 + 0.49
0.13 + 0.04
0.45 ± 0.49
0.03 ± 0.02
50 + 22
36 ± 14
14 + 10
7 ± 2
13 ±10
1.0 + 0.3
0.39 ± 0.21
0.18 + 0.04
0.36 ± 0.21
0.03 ± 0.01
53 -l· 13
39 ± 11
1 4 + 7
12 + 10
12 ± 7
1.2 ± 0.2
0.36 + 0.21
0.30 ± 0.25
0.33 ± 0.20
0.03 ± 0.01
Tab. 4. Carnitine plasma levels and esterification ratios in alcoholic and non-alcoholic cirrhosis
Total carnitine
Free carnitine
Total esterified carnitine
Acetylcarnitine
Short-chain acylcarnitine
Long-chain acylcarnitine
Total esterified carnitine/free carnitine
Acetylcarnitine/free carnitine
Short-chain acylcarnitine/free carnitine
Long-chain acylcarnitine/free carnitine
(mmol/1)
(mmol/1)
(mmol/1)
(mmol/1)
(mmol/1)
(mmol/1)
Alcoholic
cirrhosis
53 + 23
38 ± 14
15 ± 11
1 1 + 8
14 ± 10
1.2 + 0.4
0.41 ± 0.19
0.30 -l· 0.20
0.38 + 0.18
0.03 ± 0.01
Non-alcoholic
cirrhosis
47 + 12
3 5 + 9
12 + 10
6 ± 1
11 ± 10
1.1 + 0.4
0.40 + 0.39
0.14 + 0.03
0.37 + 0.38
0.03 + 0.02
P
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
Carnitine and alcohol intake
Heavy drinkers with confirmed alcoholic HBsAg-neg-
ative cirrhosis did not differ significantly from non-
drinkers with HBsAg-positive or cryptogenic cirrhosis
with respect to carnitine, even though trends towards
higher acetylcarnitine, and generally towards higher
levels of carnitine esterification were found (tab. 4).
Carnitine and renal function
No relation was found between renal function and
carnitine plasma levels or esterification ratios (tab. 5).
The only two patients with severely reduced renal
function (creatinine clearance = 8 ml/min and 18 ml/
min respectively) did not show alterations in carnitine
plasma levels or esterification ratios.
Tab. 5. Values of the Spearman's rank correlation between car-
nitine plasma levels and creatinine clearance.
R P
Total carnitine
Total esterified carnitine
Short-chain acylcarnitine
Total esterified carnitine/free carnitine
Short-chain acylcarnitine/free carnitine
Free carnitine
Acetylcarnitine
Long-chain acylcarnitine
Acetylcarnitine/free carnitine
Long-chain acylcarnitine/free carnitine
0.038
-0.133
-0.117
0.193
-0.173
-0.181
0.115
-0.266
0.014
-0.344
n. s.
n. s.
n.s.
n. s.
n.s.
n.s.
n. s.
n. s.
n. s.
<0.05
Discussion
Plasma levels of total carnitine, free carnitine and of
short chain acylcarnitine in controls were in keeping
with those of Cooper et al. (11) and of Fuller et al.
(10), whereas long chain acylcarnitine was lower. This
finding cannot be explained by differences of age and
sex in our controls compared with the other two
groups.
In fact, our controls should have had higher levels of
carnitine, because of a greater prevalence of males,
as carnitine has been reported to be higher in men
than in women (16).
Moreover, differences in the method of measuring
carnitine should be ruled out, as long chain acylcar-
nitine was also higher in Cooper's controls, which
were assayed for carnitine by the same method that
we used. It can be hypothesized that this finding is
due to differences in the alimentary habitus in the
studied groups, which were on a free diet and there-
fore conditioned by the alimentary custom of their
own country.
As far as acetylcarnitine in controls is concerned, the
subjects in which it was measured showed values in
accordance with those reported by Cooper et al. (15).
The finding that cirrhotics showed a greater range of
values of total carnitine, total esterified carnitine, and
short chain acylcarnitine, with hypercarnitinaemia
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due to the increased amount of carnitine esterified
with small acyl moieties, was in keeping with recent
studies on carnitine in liver cirrhosis (10 — 12). Thus,
we were also unable to confirm Rudmarfs observa-
tions concerning hypocarnitinaemia in cirrhosis.
However, it is plausible that Rudman studied more
severely ill patients, as deduced from the high mor-
tality rate in his series. In contrast, although 34% of
our patients were in Pugh-Child's class C, all were
discharged alive from the hospital.
Carnitine and nutrition
As far as nutritional indices and carnitine plasma level
were concerned, the weak direct correlation between
triceps skinfold and long chain acylcarnitine that we
found is in keeping with the observation that in cir-
rhotics the amount of free fatty acids coming to the
liver is linked to the amount of subcutaneous fat,
expressed by triceps skinfold (17). In fact, in cells, free
fatty acids must be activated to acyl-CoA to undergo
ß-oxidation. However, the acyl-CoA/CoA ratio is in
equilibrium with the acylcarnitine/free carnitine ratio
(4, 19), so that long chain acylcarnitine may reflect
the amount of intracellular long-chain acyl-CoA,
which depends on free fatty acids and on the rate of
ß-oxidation. In this regard, a direct correlation be-
tween triceps skinfold, an index of fatty store, and
long chain acylcarnitine is to be expected.
We did not find the inverse correlation between cre-
atinine/height ratio and short chain acylcarnitine ob-
served by Fuller et al. (10). However, it is difficult to
give a pathophysiological meaning to this correlation,
which possibly signifies that the severer the cirrhosis,
the higher is the level of short chain acylcarnitine and
the lower the muscular mass. This hypothesis is de-
ducible from the observations of D'Arienzo et al. (12),
who found higher levels of esterified carnitine in class
C cirrhotics and a direct correlation between esterified
carnitine and glucagon, possibly implicated in the
peripheral release of free fatty acids in cirrhotics (19).
In our series, however, the relationship between
plasma carnitine and liver damage was not so clear-
cut. There was no link between the severity of liver
disease evaluated by the Pugh-Child's classes and car-
nitine plasma levels or esterification ratios, although
there was a trend towards a direct association of
acetylcarnitine and acetylcarnitine/free carnitine with
the severity of disease.
Carnitine, liver function and alcohol intake
As far as the single indices of liver disease were con-
cerned, the direct correlations of -glutamyltransfer-
ase with acetylcarnitine, acetylcarnitine/free carnitine
and short chain acylcarnitine/free carnitine suggest
that ethanol is involved in the increased esterification
of carnitine with small acyl moieties in cirrhosis, be-
cause intra-hepatocytarian and plasma levels of -
glutamyltransferase are massively increased by
ethanol (20). Moreover, ethanol causes a reduction in
the redox potential of the hepatocytes (21) which,
together with direct mitochondrial lesions (22), im-
pairs ß-oxidation (23) and depresses the citric acid
cycle (24) where acetate is utilized. For these reasons
an increased amount of incompletely oxidized fatty
acids may be expected. This acyl "pressure" on CoA
should increase short chain acylcarnitine/free carni-
tine and acetylcarnitine/free carnitine ratios.
However, the comparison of heavy drinking with non-
drinking cirrhotics showed no significant differences
in carnitine, even though a clear trend towards higher
acetylcarnitine was evident in drinkers.
In our opinion, this means that cirrhosis per se is
characterized by the increase of the short chain acyl-
carnitine/free carnitine ratio and, possibly the acetyl-
carnitine/free carnitine ratio, even though alcohol
might be a co-factor in the pathophysiology of such
a finding.
Carnitine and the severity of cirrhosis
It does not seem conceivable that liver function di-
rectly accounts for alterations in carnitine plasma
levels or in carnitine esterification, because these did
not differ in the three Pugh-Child*s classes, with the
exception of a slightly higher acetylcarnitine/carnitine
ratio in class C. In fact, the Pugh-ChilcFs classification
can be considered a reliable index of liver function,
because it is strictly correlated both with the amino-
pyrine breath test (26) and with the indocyanine green
intrinsic hepatic clearance (27), two of the most val-
uable quantitative liver function tests.
The inverse correlation between albumin and acetyl-
carnitine was in keeping with the trend towards higher
levels of acetylcarnitine in Pugh-ChilcFs class C, but
it was so weak that something other than liver func-
tion seems to be involved. It may be hypothesized
that an increased utilization of fatty acids as a fuel in
cirrhotics (25), together with possible alterations in
citric acid cycle are implicated in the pathophysiology
of the high levels of short chain acylcarnitine and
acetylcarnitine in liver cirrhosis.
Moreover, a possible link between the increase in
short chain acylcarnitine and cholestasis cannot be
ruled out; this is suggested by the direct, albeit weak,
correlation with alkaline phosphatase and by the fact
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that alkaline phosphatase and γ-glutamyltransferase
showed a relationship with the esterification of car-
nitine. On the other hand, it is well known that
cholestasis affects lipid metabolism, causing various
abnormalities in the plasma lipid pattern.
Carnit ine and renal function
Carnitine is cleared primarily by the kidneys (28), so
that it may be thought that the subtle reduction of
renal function frequently found in liver cirrhosis (29)
could be involved in the alterations of plasma carni-
tine. However, the lack of any relationship between
creatinine clearance and plasma carnitine levels or
esterification, together with the observation that the
two patients with a severely impaired renal function
had normal carnitine levels, ruled out this hypothesis
in our series.
Conclusions
In conclusion, a selective increase in short chain acyl-
carnitine, the short chain acylcarnitine/free carnitine
ratio (and possibly of acetylcarnitine and the acetyl-
carnitine/free carnitine ratio), resulting in high levels
of total esterified carnitine and total carnitine was
found in liver cirrhosis irrespective of its aetiology.
The nutritional status did not seem to be involved in
such alterations, which are conceivably dependent on
liver cirrhosis per se.
More research is necessary to clarify why these alter-
ations occur and their clinical significance.In partic-
ular, it is necessary to determine whether they are
only a signal of a particular kind of energetic metab-
olism in chronic liver disease, or whether they express
a relative lack of free carnitine and free CoA, poten-
tially harmful to liver cells.
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